Header

Pancreatic Cancer Clinical Trials

Category:Adult
Status:Active

Displaying all 15 trials

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenoca

The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with p...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase: 3

Protocol Number: 16-146

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

Hospitalized patients with pancreatic, stomach, ovarian or non-small lung cancer, or non-Hodgkin's lymphoma and who are at high risk for a venous thromboembolisn will be randomized to standard ...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Other Cancers, Stomach Cancer, Non-Hodgkin's Lymphoma, Pancreatic Cancer

Phase: 2

Protocol Number: 15-547

Gemcitabine Plus BPM31510 Administered Intravenously in Advanced Pancreatic Cancer Patients

This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of the combination of BPM31510 administered as a 144-hour continuous intravenous (IV) infusio...

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase: 2

Protocol Number: 17-066

Safety and Efficacy of FGF401 in Patients With Solid Malignancies

Estimate the maximum tolerated dose and/or recommended phase two dose and efficacy of FGF401 on patients with solid malignancies

Diagnosis: Gastrointestinal Malignancies, Stomach Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer

Phase: 1 / 2

Protocol Number: 14-464

A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer

This is a randomized phase II multi-institution prospective open label study in which up to 90 subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer who previously ...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase: 1 / 2

Protocol Number: 14-568

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using...

Diagnosis: Colorectal Cancer, Esophageal Cancer, Gastrointestinal Malignancies, Pancreatic Cancer

Phase: N/A

Protocol Number: 13-415

A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

This is a Phase I, multicenter, open-label, dose-escalation study of DMUC4064A administered by intravenous (IV) infusion every three weeks (q3w) to cancer patients. The study will employ a traditio...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Pancreatic Cancer

Phase:

Protocol Number: 14-263

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Pr...

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase:

Protocol Number: 15-191

Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)

This study will assess the efficacy and safety of BL-8040 as a single agent and in combination with pembrolizumab (Keytruda®) in subjects with metastatic pancreatic adenocarcinoma.

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase:

Protocol Number: 16-508

Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy

This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations

Diagnosis: Pancreatic Cancer

Phase:

Protocol Number: 16-448

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer

The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients with resectable (surg...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase:

Protocol Number: 16-490

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

This research study is studying a combination of drugs with radiation therapy as a possible treatment for Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, or MSI High Colorectal Cancer. ...

Diagnosis: Colorectal Cancer, Pancreatic Cancer

Phase:

Protocol Number: 17-021

Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

The purpose of this study is to compare any good and bad effects of using chemotherapy compared to chemotherapy and radiation prior to surgery. This study will allow the researchers to know whether...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase:

Protocol Number: 17-047

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety, pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in sequential cohorts of adu...

Diagnosis: Pancreatic Cancer

Phase:

Protocol Number: 17-029

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

A multi-center Phase 1b/2 study testing the combination of AMG 820 and pembrolizumab in subjects with select advanced solid tumors.

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies, Lung Cancer, Colorectal Cancer

Phase:

Protocol Number: 16-502

'